Alg3 Glycosyltransferase Mutations for Recombinant Protein Yield
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for recombinant protein production in fungal hosts are complex and inefficient, requiring lengthy strain and process development for each new protein, with limited improvement in productivity for heterologous proteins.
Innovation Solution
Introduction of specific single nucleotide polymorphisms (SNPs) in the alg3 gene of fungal host cells, such as R15*, T17I, and L137F mutations, which enhance the expression, activity, and yield of recombinant proteins like glucoamylase and lysozyme without inactivating Alg3 glycosylation activities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional mutagenesis and screening methods are used to improve protein production, then productivity of endogenous proteins can be increased, but the approach is not useful for heterologous proteins and requires lengthy strain development for each new protein
Solution Approach 1:
The patent applies parameter changes by introducing specific point mutations (SNPs) in the alg3 gene sequence. These mutations change the amino acid composition of the Alg3 protein (e.g., R15*, T17I, L137F substitutions) to optimize its glycosylation activity for heterologous protein production, achieving improved productivity without lengthy strain development
Solution Approach 2:
The modified Alg3 variant demonstrates universality by being applicable to the production of multiple different heterologous proteins (glucoamylase, lysozyme, and other glycoproteins). A single engineered Alg3 variant can serve multiple protein production purposes, eliminating the need for separate strain development programs for each protein
2Productivity
If multiple copies of recombinant gene constructs are targeted to highly expressed endogenous gene loci to improve transcription, then expression level increases, but the process becomes more complex
Solution Approach 1:
Instead of increasing gene copy number or using complex multi-component systems, the patent changes the biochemical parameter of the glycosylation enzyme (Alg3) itself through point mutations. This simple genetic modification in the alg3 gene achieves high expression levels of heterologous proteins without requiring complex gene construct designs or multiple gene copies
3Productivity
If fusion strategies are used to facilitate translocation and protect heterologous proteins from degradation, then secretion efficiency improves, but the process complexity increases
Solution Approach 1:
The patent changes the functional parameters of the Alg3 glycosyltransferase through specific amino acid substitutions to optimize its ability to glycosylate heterologous proteins. This modification of the glycosylation enzyme's activity directly improves secretion efficiency and protein stability without requiring fusion proteins or additional engineering components
4Productivity
If native proteases are disrupted to reduce proteolytic degradation and improve protein yield, then productivity increases, but the strain development process becomes more complex and time-consuming
Solution Approach 1:
The patent changes the biochemical environment by modifying the Alg3 enzyme's glycosylation activity through point mutations. The enhanced glycosylation of heterologous proteins by the mutated Alg3 provides protection against proteolytic degradation, improving protein yield without requiring disruption of protease genes or lengthy strain development programs
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified fungal host cells with alg3 gene mutations show increased productivity and activity of recombinant proteins, potentially applicable to other glycoproteins, simplifying the production process and improving yield.
Implementation Method 1
Alg3 catalyzes the addition of the first dol-P-Man derived mannose in an alpha 1,3-linkage to Man5GlcNAc2-PP-Dol, resulting in MansGlcNAc2-PP-Dol
Data Source
AI summary
The present invention relates to a polynucleotide variant encoding a glycosyltransferase variant, and to nucleic acid constructs, vectors and host cells comprising said polynucleotide variant. The invention also relates to methods of producing a polypeptide of interest in host cells comprising said polynucleotide and/or glycosyltransferase variant.